secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-032197
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity Q2 net loss widens to $23.7M; VIKTORIA-1 PIK3CA WT cohort enrollment delayed to Q4 2024
--------------------------------------------------------------------------------

- Net loss of $23.7M ($0.62/share) vs $14.6M ($0.66/share) YoY; non-GAAP adjusted loss per share $0.58.
- R&D expenses rose to $22.5M, driven by VIKTORIA-1 Phase 3 and initiation of Phase 1b/2 mCRPC trial.
- Raised $129M gross from equity and debt financings, extending cash runway through 2026.
- VIKTORIA-1 PIK3CA WT cohort enrollment target shifted to Q4 2024; topline data expected late Q4 2024 to Q1 2025.
- Plan to initiate Phase 3 VIKTORIA-2 trial in first-line HR+/HER2- advanced breast cancer; first patient expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224032197/0001493152-24-032197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224032197/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer